Details of Disease

General Information of Disease (ID: DISNSMUD)

• Disease Name: Mycobacterium infection
• Synonyms: mycobacterium infection; mycobacterial infection; mycobacteriosis
• Disease Class: 1B10-1B21: Mycobacterium infection
• Definition: Infection due to organisms from the genus Mycobacteria.
• Disease Hierarchy:
  DIS5QJ9S: Bacterial infection
  DISEM33Q: Infectious disease
  DISNSMUD: Mycobacterium infection
• ICD Code: ICD-11: ICD-11: 1B10-1B21
• Disease Identifiers:
  MONDO ID: MONDO_0020590
  MESH ID: D009164
  UMLS CUI: C0026918
  MedGen ID: 6479
  SNOMED CT ID: 88415009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 10 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Capreomycin	DMNZBRY	Approved	Small molecular drug	[1]
Clofazimine	DMEBOFW	Approved	Small molecular drug	[2]
Delamanid	DMXE76K	Approved	Small molecular drug	[3]
Leprovac	DM1C993	Approved	NA	[1]
Pretomanid	DMDYA31	Approved	Small molecular drug	[4]
Pyrazinamide	DM4IF32	Approved	Small molecular drug	[5]
Rifabutin	DM1YBHK	Approved	Small molecular drug	[6]
Thiacetazone	DM95FAG	Approved	Small molecular drug	[1]
Tuberculin	DMHWWTE	Approved	NA	[1]
Typhoid vaccine	DMMVB49	Approved	Vaccine	[1]

This Disease is Treated as An Indication in 15 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Liposomal amikacin	DMRJ1HC	Phase 3	NA	[7]
AERAS-402	DM7GY0Z	Phase 2	NA	[8]
AZD-5847	DMLXR5Y	Phase 2	NA	[9]
LL-3858	DME8NEJ	Phase 2	Small molecular drug	[10]
MVA-85A	DMKDN1C	Phase 2	Vaccine	[11]
RUTI	DMEM7X9	Phase 2	NA	[12]
Tuberculosis vaccine	DMQ8BA6	Phase 2	NA	[13]
VPM-1-002	DM7SXNB	Phase 2	NA	[14]
GTU-TB vaccine	DM0S24D	Phase 1/2	Vaccine	[15]
SPR720	DMJDV0K	Phase 1/2	Small molecular drug	[16]
Ad5Ag85A	DMKQKXQ	Phase 1	NA	[17]
AERAS-407 rBCG	DMH4J7F	Phase 1	NA	[18]
CALANOLIDE A	DMQTUH8	Phase 1	Small molecular drug	[19]
FP-85A	DMGP30S	Phase 1	NA	[20]
Macozinone	DM0HKU7	Phase 1	Small molecular drug	[21]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
2E9IgA1	DM4NURZ	Preclinical	Antibody	[22]
SMITB14	DM3X4JL	Preclinical	Antibody	[22]

This Disease is Treated as An Indication in 5 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CRL-1018	DMASY8D	Terminated	NA	[23]
FCE-20696	DMI81Z8	Terminated	Small molecular drug	[24]
Modified BCG vaccine	DM8U4XN	Terminated	NA	[25]
PA-342	DMOO45R	Terminated	NA	[26]
SRI-3072	DMBEUN6	Terminated	Small molecular drug	[27]

This Disease is Treated as An Indication in 33 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ADX40-TB	DMID6U3	Investigative	NA	[2]
AERAS-405	DMPHQLL	Investigative	NA	[2]
Antituberculosis agents	DM12HNX	Investigative	NA	[2]
BV-6481	DMG7CAQ	Investigative	NA	[2]
CD1-TB	DM6N57X	Investigative	NA	[2]
CO-12	DMS1MEM	Investigative	NA	[2]
CPZEN-45	DM5QKX9	Investigative	Small molecular drug	[2]
DasKloster 0249-01	DM6Y8CN	Investigative	NA	[2]
DF-152	DM6NYYN	Investigative	NA	[2]
FAS-20013	DMB2IBS	Investigative	NA	[2]
Glucopyranoside derivatives	DM5VOYI	Investigative	NA	[2]
GSK-2231260A	DMKU69W	Investigative	NA	[2]
Heat-killed Mycobacterium vaccine	DM45ISI	Investigative	NA	[2]
I-A09	DMML70T	Investigative	Small molecular drug	[2]
KBF-611	DM5QTM0	Investigative	Small molecular drug	[2]
L2-05	DM3JOEL	Investigative	NA	[2]
Malate synthase	DME6A51	Investigative	NA	[2]
MDDR 184045	DMSVRL0	Investigative	NA	[2]
MTbuVax	DMOX7ME	Investigative	NA	[2]
ND-201	DMRW86Z	Investigative	NA	[2]
ND-601	DM3PK2Z	Investigative	NA	[2]
ND-701	DMVBPG1	Investigative	NA	[2]
ND-801	DMKG36A	Investigative	NA	[2]
NTF-1836	DMA7B0U	Investigative	NA	[2]
PMX-10072	DMKV9V3	Investigative	NA	[2]
PMX-30024	DMQGHK7	Investigative	NA	[2]
Q-201	DMGTI01	Investigative	NA	[2]
Ruthenium (II) phosphine/picolinate complexes	DM4KCC0	Investigative	NA	[2]
Sharon-1000	DMJQNZB	Investigative	NA	[2]
SND-159	DM1HJLQ	Investigative	NA	[2]
TBD-2	DMQ19MW	Investigative	NA	[2]
Tuberculosis therapeutics	DMDZ95G	Investigative	NA	[2]
Tuberculosis therapy, Ithemba	DMS5TLG	Investigative	NA	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 22 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
HSPE1	TTWYMFE	Disputed	Biomarker	[28]
IFNAR2	TTMQB37	Disputed	Biomarker	[29]
HSPD1	TT9HL5R	moderate	Biomarker	[30]
IL12B	TTGW72V	moderate	Genetic Variation	[31]
IL9	TT0JTFD	moderate	Genetic Variation	[32]
IRF8	TTHUBNK	moderate	Biomarker	[33]
NOD2	TTYPUHA	moderate	Genetic Variation	[34]
TLR2	TTY7ZHS	moderate	Biomarker	[35]
CAMKK2	TTV298Y	Strong	Biomarker	[36]
CAMP	TTULOB6	Strong	Biomarker	[37]
CD209	TTBXIM9	Strong	Biomarker	[38]
CLEC9A	TTGUSRB	Strong	Biomarker	[39]
IFNGR2	TT13TL0	Strong	Genetic Variation	[40]
IRAK4	TTILUKB	Strong	Biomarker	[41]
ISG15	TTVOH3T	Strong	Biomarker	[42]
LANCL1	TTZW8NS	Strong	Genetic Variation	[32]
LTA4H	TTXZEAJ	Strong	Genetic Variation	[43]
RORC	TTGV6LY	Strong	Genetic Variation	[44]
SFTPD	TTGLMU7	Strong	Genetic Variation	[45]
SMPD2	TTE5VI6	Strong	Biomarker	[46]
STAT1	TTN7R6K	Strong	Genetic Variation	[47]
TYK2	TTBYWP2	Definitive	Biomarker	[48]

This Disease Is Related to 24 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ARHGEF2	OTBQTFRT	moderate	Genetic Variation	[32]
AP4E1	OT4DUNVU	Strong	Genetic Variation	[49]
ARMH1	OTTJC0D6	Strong	Genetic Variation	[32]
ATG16L1	OTEOYC5D	Strong	Genetic Variation	[34]
BATF2	OT4XBZC9	Strong	Biomarker	[50]
BTNL9	OT3PWOH6	Strong	Biomarker	[51]
CD1B	OT4D5EG7	Strong	Biomarker	[52]
DRAM1	OTIJTXEN	Strong	Biomarker	[53]
EBNA1BP2	OTBRVMZH	Strong	Genetic Variation	[32]
GATA2	OTBP2QQ2	Strong	Genetic Variation	[54]
IFNGR1	OTCTQBWW	Strong	Genetic Variation	[55]
IKBKG	OTNWJWSD	Strong	Genetic Variation	[56]
IRF9	OTK4MYQJ	Strong	Biomarker	[57]
LRBA	OTOUZN9G	Strong	Biomarker	[58]
MNAT1	OTXLOYCB	Strong	Genetic Variation	[32]
MPEG1	OT7DAO0F	Strong	Genetic Variation	[59]
NT5C3A	OT67KZJA	Strong	Biomarker	[60]
NTM	OTHF0UQU	Strong	Biomarker	[61]
PSMD7	OT7PZZ4K	Strong	Genetic Variation	[32]
RAB29	OTDZT6LP	Strong	Biomarker	[62]
RABEPK	OTCZSREH	Strong	Genetic Variation	[32]
SDC4	OTKUVUGZ	Strong	Altered Expression	[63]
SMPD3	OTHQBETH	Strong	Biomarker	[64]
SPPL2A	OTCVF6MM	Definitive	Biomarker	[65]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [3] ClinicalTrials.gov (NCT01424670) Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT02342886) Shortening Treatment by Advancing Novel Drugs. U.S. National Institutes of Health.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7287).
• [6] Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] ClinicalTrials.gov (NCT02414828) A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT01516203) Phase 2a EBA Trial of AZD5847. U.S. National Institutes of Health.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031647)
• [11] ClinicalTrials.gov (NCT01650389) Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination. U.S. National Institutes of Health.
• [12] Clinical pipeline report, company report or official report of Archivel Farma SL.
• [13] New vaccine shows promise as stronger weapon against both tuberculosis and leprosy. Health + Behavior. Enrique Rivero, August 19, 2014.
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032089)
• [15] Clinical pipeline report, company report or official report of FIT Biotech.
• [16] ClinicalTrials.gov (NCT04553406) Phase 2a Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT00800670) Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT01340820) Study of AERAS 422 in Healthy Adults. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT00005120) The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT00653770) A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT04150224) Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169. U.S. National Institutes of Health.
• [22] Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006602)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003299)
• [25] New developments in BCG vaccine: implications for tuberculosis control. Epidemiol Infect. 2007 Feb;135(2):177-80.
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007262)
• [27] 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother. 2002 Jul;50(1):111-4.
• [28] Immune profiling of leprosy and tuberculosis patients to 15-mer peptides of Mycobacterium leprae and M. tuberculosis GroES in a BCG vaccinated area: implications for development of vaccine and diagnostic reagents.Immunology. 2004 Apr;111(4):462-71. doi: 10.1111/j.0019-2805.2004.01839.x.
• [29] Gamma interferon receptor defect presenting as recurrent tuberculosis.Indian J Pediatr. 2014 Jul;81(7):696-8. doi: 10.1007/s12098-013-1060-5. Epub 2013 May 17.
• [30] HSP65-PRA identification of non-tuberculosis mycobacteria from 4892 samples suspicious for mycobacterial infections.Clin Microbiol Infect. 2013 Aug;19(8):723-8. doi: 10.1111/j.1469-0691.2012.04005.x. Epub 2012 Sep 11.
• [31] Mendelian Susceptibility to Mycobacterial Disease Caused by a Novel Founder IL12B Mutation in Saudi Arabia.J Clin Immunol. 2018 Apr;38(3):278-282. doi: 10.1007/s10875-018-0490-2. Epub 2018 Mar 27.
• [32] Chronic Disseminated Salmonellosis in a Patient With Interleukin-12p40 Deficiency.Pediatr Infect Dis J. 2018 Jan;37(1):90-93. doi: 10.1097/INF.0000000000001701.
• [33] Host susceptibility to non-tuberculous mycobacterial infections.Lancet Infect Dis. 2015 Aug;15(8):968-80. doi: 10.1016/S1473-3099(15)00089-4. Epub 2015 Jun 3.
• [34] Genetic Variation in Autophagy-Related Genes Influences the Risk and Phenotype of Buruli Ulcer.PLoS Negl Trop Dis. 2016 Apr 29;10(4):e0004671. doi: 10.1371/journal.pntd.0004671. eCollection 2016 Apr.
• [35] Infection and RNA-seq analysis of a zebrafish tlr2 mutant shows a broad function of this toll-like receptor in transcriptional and metabolic control and defense to Mycobacterium marinum infection.BMC Genomics. 2019 Nov 20;20(1):878. doi: 10.1186/s12864-019-6265-1.
• [36] A haplotype spanning P2X7R, P2X4R and CAMKK2 may mark susceptibility to pulmonary non-tuberculous mycobacterial disease.Immunogenetics. 2017 May;69(5):287-293. doi: 10.1007/s00251-017-0972-z. Epub 2017 Feb 23.
• [37] Status of cathelicidin IL-37, cytokine TNF, and vitamin D in patients with pulmonary tuberculosis.J Biol Regul Homeost Agents. 2018 Mar-Apr;32(2):321-325.
• [38] Decreased pathology and prolonged survival of human DC-SIGN transgenic mice during mycobacterial infection.J Immunol. 2008 May 15;180(10):6836-45. doi: 10.4049/jimmunol.180.10.6836.
• [39] CLEC9A modulates macrophage-mediated neutrophil recruitment in response to heat-killed Mycobacterium tuberculosis H37Ra.PLoS One. 2017 Oct 24;12(10):e0186780. doi: 10.1371/journal.pone.0186780. eCollection 2017.
• [40] Structure of the IFN receptor complex guides design of biased agonists.Nature. 2019 Mar;567(7746):56-60. doi: 10.1038/s41586-019-0988-7. Epub 2019 Feb 27.
• [41] Lack of IL-1 Receptor-Associated Kinase-4 Leads to Defective Th1 Cell Responses and Renders Mice Susceptible to Mycobacterial Infection.J Immunol. 2016 Sep 1;197(5):1852-63. doi: 10.4049/jimmunol.1502157. Epub 2016 Jul 20.
• [42] ISG15-Induced IL-10 Is a Novel Anti-Inflammatory Myeloid Axis Disrupted during Active Tuberculosis.J Immunol. 2018 Feb 15;200(4):1434-1442. doi: 10.4049/jimmunol.1701120. Epub 2018 Jan 8.
• [43] The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans.Cell. 2010 Mar 5;140(5):717-30. doi: 10.1016/j.cell.2010.02.013.
• [44] IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science. 2015 Aug 7;349(6248):606-613. doi: 10.1126/science.aaa4282. Epub 2015 Jul 9.
• [45] Functional Analysis of Genetic Variations in Surfactant Protein D in Mycobacterial Infection and Their Association With Tuberculosis.Front Immunol. 2018 Jul 2;9:1543. doi: 10.3389/fimmu.2018.01543. eCollection 2018.
• [46] Crosstalk Between Sphingomyelinases and Reactive Oxygen Species in Mycobacterial Infection.Antioxid Redox Signal. 2018 Apr 1;28(10):935-948. doi: 10.1089/ars.2017.7050. Epub 2017 Apr 6.
• [47] A heterozygous dominant-negative mutation in the coiled-coil domain of STAT1 is the cause of autosomal-dominant Mendelian susceptibility to mycobacterial diseases.Clin Immunol. 2017 Jan;174:24-31. doi: 10.1016/j.clim.2016.11.004. Epub 2016 Nov 14.
• [48] Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.Eur J Immunol. 2016 Nov;46(11):2639-2649. doi: 10.1002/eji.201646519. Epub 2016 Oct 5.
• [49] A novel homozygous p.R1105X mutation of the AP4E1 gene in twins with hereditary spastic paraplegia and mycobacterial disease.PLoS One. 2013;8(3):e58286. doi: 10.1371/journal.pone.0058286. Epub 2013 Mar 5.
• [50] Targeting Batf2 for infectious diseases and cancer.Oncotarget. 2015 Sep 29;6(29):26575-82. doi: 10.18632/oncotarget.5576.
• [51] The Armadillo (Dasypus novemcinctus): A Witness but Not a Functional Example for the Emergence of the Butyrophilin 3/V9V2 System in Placental Mammals.Front Immunol. 2018 Feb 23;9:265. doi: 10.3389/fimmu.2018.00265. eCollection 2018.
• [52] Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination.J Immunol Methods. 2018 Jul;458:44-52. doi: 10.1016/j.jim.2018.04.004. Epub 2018 Apr 21.
• [53] The DNA damage-regulated autophagy modulator DRAM1 links mycobacterial recognition via TLR-MYD88 to autophagic defense [corrected].Cell Host Microbe. 2014 Jun 11;15(6):753-67. doi: 10.1016/j.chom.2014.05.005.
• [54] Impaired immune responses to herpesviruses and microbial ligands in patients with MonoMAC.Br J Haematol. 2019 Aug;186(3):471-476. doi: 10.1111/bjh.15947. Epub 2019 May 20.
• [55] Evaluation of interleukin-12 receptor 1 and interferon gamma receptor 1 deficiency in patients with disseminated BCG infection.Allergol Immunopathol (Madr). 2019 Jan-Feb;47(1):38-42. doi: 10.1016/j.aller.2018.06.005. Epub 2018 Sep 27.
• [56] IKBKG (NEMO) 5' Untranslated Splice Mutations Lead to Severe, Chronic Disseminated Mycobacterial Infections.Clin Infect Dis. 2018 Jul 18;67(3):456-459. doi: 10.1093/cid/ciy186.
• [57] Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003 Mar;33(3):388-91. doi: 10.1038/ng1097. Epub 2003 Feb 18.
• [58] Flow cytometry-based diagnosis of primary immunodeficiency diseases.Allergol Int. 2018 Jan;67(1):43-54. doi: 10.1016/j.alit.2017.06.003. Epub 2017 Jul 3.
• [59] MPEG1/perforin-2 mutations in human pulmonary nontuberculous mycobacterial infections.JCI Insight. 2017 Apr 20;2(8):e89635. doi: 10.1172/jci.insight.89635. eCollection 2017 Apr 20.
• [60] Identification of Mycobacterium avium complex in sarcoidosis.J Clin Microbiol. 1996 Sep;34(9):2240-5. doi: 10.1128/jcm.34.9.2240-2245.1996.
• [61] Notification of Nontuberculous Mycobacteria: An Australian Perspective.Ann Am Thorac Soc. 2017 Mar;14(3):318-323. doi: 10.1513/AnnalsATS.201612-994OI.
• [62] Mycobacterial PknG Targets the Rab7l1 Signaling Pathway To Inhibit Phagosome-Lysosome Fusion.J Immunol. 2018 Sep 1;201(5):1421-1433. doi: 10.4049/jimmunol.1800530. Epub 2018 Jul 23.
• [63] Syndecans promote mycobacterial internalization by lung epithelial cells.Cell Microbiol. 2016 Dec;18(12):1846-1856. doi: 10.1111/cmi.12627. Epub 2016 Jul 15.
• [64] Mycobacterial Infection is Promoted by Neutral Sphingomyelinase 2 Regulating a Signaling Cascade Leading to Activation of 1-Integrin.Cell Physiol Biochem. 2018;51(4):1815-1829. doi: 10.1159/000495683. Epub 2018 Nov 30.
• [65] Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency. Nat Immunol. 2018 Sep;19(9):973-985. doi: 10.1038/s41590-018-0178-z. Epub 2018 Aug 20.